Supplemental Table 1. Posterior probabilities for selection of predictive variables in a model for the association between participant characteristics and increased internal or common carotid intimal-medial thickness (cIMT) using Bayesian model averaging.

Predictor	IMT using ARIC definition		
	Mean Common cIMT	Max Internal cIMT	Internal cIMT Plaque (defined as maximum > 1.5mm)
Male	15.4%	0%	0%
Age	100%	100%	100%
African-American	100%	30.4%	83.6%
Hispanic	46.3%	0%	0%
Systolic Blood Pressure	79.9 %	54.7%	14.3%
Diastolic Blood Pressure	4.0%	2.6%	3.8%
Current Smoker	14.3%	100%	100%
Past Smoker	0.9%	0%	0%
Diabetes	0%	0%	0%
Total Cholesterol	0%	0%	0%
HDL Cholesterol	10.0%	0%	2.9%
Injection Drug Use	8.4%	0%	0%
AIDS by OI alone	0%	40.0%	12.6%
Duration of HIV Infection	0%	0%	0%
HCV Infection	0.5%	0%	0%
CD4 (current)	0%	0%	1.5%
CD4 (nadir)	0%	3.4%	15.0%
Undetectable Viral Load	0.7%	0%	0%
C-Reactive Protein	0%	0%	1.3%
Interleukin-6	0%	4.8%	1.9%
Fibrinogen	0%	0%	0%
Lamivudine	0%	0%	0%
Zidovudine	0%	0%	0%
Stavudine	0%	0%	1.2%
Tenofovir	0%	1.7%	0%
Didanosine	33.1%	0%	1.8%
Abacavir	0%	0.9%	0%
Emtricitabine	0%	0.7%	2.3%
Zalcitabine	0%	0%	0%
Ritonavir	8.7%	0%	1.4%

Indinavir	0%	1.9%	1.1%
Nelfinavir	0%	17.6%	11.3%
Lopinavir	0%	0.9%	2.2%
Saquinavir	0%	0%	1.6%
Atazanavir	0%	0.7%	1.2%
Amprenavir	0%	0%	0%
Fosamprenavir	0%	0%	1.7%
Efavirenz	0%	0%	0%
Nevaripine	2.5%	0%	1.2%
Delavirdine	0%	0%	0%

Definitions: PI: Protease Inhibitor, NNRTI: Non-nucleoside reverse transcriptase inhibitors, NRTI: Nucleoside reverse transcriptase inhibitors, ARV: Antiretroviral medication, cIMT: carotid intimal-medial thickness, HDL: High-density lipoprotein, OI: Opportunistic Infection, HIV: Human immunodeficiency virus, HCV: Hepatitis C virus, HAART: highly active antiretroviral therapy, CRP: C-reactive protein.

Supplemental Table 2. Estimates of the mean difference associated with predictors for common and internal carotid intimal-medial thickness excluding plaque as defined by cIMT >1.5mm and odds ratio of factors associated with plaque by that definition. All variables with a posterior probability greater than or equal to 50% for **either** internal or common cIMT from table 3 are included in these analyses.

	IMT using ARIC definition					
	Estimate	**95% Confidence Limits**	**p-value**	**Estimate**	**95% Confidence Limits**	**p-value**
	Mean Common cIMT			**Max Internal cIMT**		
Age *(per 10 years)*	0.082	(0.064, 0.100)	<.0001	0.330	(0.240, 0.420)	<.0001
African-American	0.076	(0.048, 0.104)	<.0001	-0.157	(-0.293, -0.021)	0.024
Hispanic	0.058	(0.019, 0.097)	0.0038	0.031	(-0.170, 0.232)	0.76
Current Smoker	0.039	(0.012, 0.066)	0.0041	0.275	(0.120, 0.429)	0.0005
Systolic Blood Pressure *(per 10 mmHg)*	0.022	(0.009, 0.034)	0.0005	0.099	(0.021, 0.178)	0.013
Diastolic Blood Pressure *(per 10 mmHg)*	-0.026	(-0.047, -0.005)	0.013	-0.106	(-0.214, 0.003)	0.056
Tenofovir Use *(per year)*	-0.006	(-0.014, 0.003)	0.20	-0.034	(-0.079, 0.011)	0.13
HDL Cholesterol *(per 10 mg/dL)*	-0.005	(-0.012, 0.002)	0.14	0.011	(-0.043, 0.064)	0.70
				Odds Ratio	**95% Confidence Limits**	**p-value**
				Internal cIMT Plaque (defined as maximum > 1.5 mm)		
Age *(per 10 years)*				2.22	(1.69, 2.91)	<.0001
African-American				0.56	(0.36, 0.86)	0.0081
Hispanic				0.92	(0.43, 1.99)	0.83
Current Smoker				2.38	(1.58, 3.58)	<.0001
Systolic Blood Pressure *(per 10 mmHg)*				1.15	(0.95, 1.39)	0.15
Diastolic Blood Pressure *(per 10 mmHg)*				0.93	(0.67, 1.29)	0.66
Tenofovir Use *(per year)*				0.99	(0.86, 1.14)	0.85
HDL Cholesterol *(per 10 mg/dL)*				0.95	(0.85, 1.06)	0.36